Posts

Posted on

EXFO partners with Openreach for ground-breaking Full Fibre initiative

PR Newswire

Openreach to deploy permanent Full Fibre monitoring technology to help deliver ultrafast and ultra-reliable broadband to millions of UK homes and businesses.

LONDON, UK, Jan. 7, 2021 /PRNewswire/ – EXFO Inc. (NASDAQ: EXFO) (TSX: EXF), the communications industry’s test, monitoring and analytics experts, and Openreach, the United Kingdom’s largest digital infrastructure firm, today announced their collaboration on a major initiative to accelerate Full Fibre deployment, and enhance the quality of build and experience for customers across the UK.

The project is essential for delivering next-generation Fibre-to-the-Premises (FTTP) networks, which provide the digital infrastructure required to work, learn and socialize. As part of its industry-leading Fibre First programme, Openreach has committed to delivering 20 million homes passed with FTTP by the mid-to late 2020s, assuming it has the right investment conditions. Openreach has also committed to building out this new digital infrastructure to 4.5 million premises by the end of March 2021.

Following a competitive tender process, Openreach has awarded EXFO a contract to supply optical test heads and test access switching for this initiative. With its cloud-based Nova Fiber solution, EXFO will equip Openreach to assure its build, thereby accelerating the programme and avoiding costly return visits to fix connection problems—additional “truck rolls” more than double operators testing costs.1 Following installation, Openreach will be able to remotely monitor its fibre infrastructure supporting the in-life operations of its Full Fibre service.

This announcement comes as Openreach hit a record build rate for its Full Fibre broadband programme. Openreach engineers are now delivering faster, more reliable connectivity to another 40,000 homes and businesses every week, or the equivalent of a home every 15 seconds.


Peter Bell, Director, Network Technology, Openreach: “We know that now more than ever that being connected matters. We’re convinced that our new Full Fibre network can play a crucial role in keeping the nation connected. This year, our build has been gathering pace and momentum, and we’re determined to match that rapid speed of deployment with the highest standards of build quality build and customer service.

EXFO will help us get there. As a long-term Openreach partner, EXFO was selected thanks to its proven ability to provide fast, automated qualification of fibre builds, and for its unique iOLM OTDR technology. We’re committed to working with the best-in-class to maintain our position as the UK’s leading Full Fibre builder and we’re excited to lead the way as we continue to deliver high-quality network connections to homes and businesses across the UK.”

Wim te Niet, Vice President, Sales – EMEA, EXFO: “Openreach is an early mover in adopting permanent fibre monitoring technology, which will eventually cover all households in the UK. Currently, the FTTH/B penetration rate in the UK stands at 18%2, and Openreach has an ambitious plan to build out Full Fibre to millions of households and businesses. We see a similar wave in other key European markets like Germany. I believe network operators across Europe will soon follow Openreach’s lead to ensure first-time-right installations, reduce turn-up failures, and substantially reduce truck rolls for service calls. As for markets with high FTTH/B penetration rates, telecom operators are finding they need sophisticated automated monitoring tools to ensure superior customer experience. EXFO’s innovative Nova Fiber solution gives them these abilities.”

About EXFO

EXFO (NASDAQ: EXFO) (TSX: EXF) develops smarter test, monitoring and analytics solutions for fixed and mobile network operators, webscale companies and equipment manufacturers in the global communications industry. Our customers count on us to deliver superior network performance, service reliability and subscriber insights. They count on our unique blend of equipment, software and services to accelerate digital transformations related to fibre, 4G/LTE and 5G deployments. They count on our expertise with automation, real-time troubleshooting and big data analytics, which are critical to their business performance. We’ve spent over 35 years earning this trust, and today 1,900 EXFO employees in over 25 countries work side by side with our customers in the lab, field, data center and beyond.

About Openreach
Openreach Limited is the UK’s digital network business. We’re 35,000 people, working in every community to connect homes, schools, shops, banks, hospitals, libraries, mobile phone masts, broadcasters, governments and businesses – large and small – to the world. Our mission is to build the best possible network, with the highest quality service, making sure that everyone in the UK can be connected. We work on behalf of more than 660 communications providers like SKY, TalkTalk, Vodafone, BT and Zen, and our broadband network is the biggest in the UK, passing more than 31.8m UK premises. Over the last decade we’ve invested more than £14 billion into our network and, at more than 185 million kilometres, it’s now long enough to wrap around the world 4,617 times. Today we’re building an even faster, more reliable and future-proof broadband network which will be the UK’s digital platform for decades to come. We’re making progress towards our FTTP target to reach 20m premises by mid-to late 2020s. We’ve also hired more than 3,000 trainee engineers this past financial year to help us build that network and deliver better service across the country. Openreach is a highly regulated, wholly owned, and independently governed unit of the BT Group. More than 90 per cent of our revenues come from services that are regulated by Ofcom and any company can access our products under equivalent prices, terms and conditions. For the year ended 31 March 2020, we reported revenue of £5bn. 

For more information, visit  www.openreach.co.uk/.
Email: [email protected]

Forward-Looking Statements – EXFO
This news release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and we intend that such forward-looking statements be subject to the safe harbors created thereby. Forward-looking statements are statements other than historical information or statements of current condition. Words such as may, expect, believe, plan, anticipate, intend, could, estimate, continue, or similar expressions or the negative of such expressions are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections or other characterizations of future events and circumstances are considered forward-looking statements. They are not guarantees of future performance and involve risks and uncertainties. Actual results may differ materially from those in forward-looking statements due to various factors including, but not limited to, macroeconomic uncertainty, including trade wars and recessions; our ability to successfully integrate businesses that we acquire; capital spending and network deployment levels in the communications industry (including our ability to quickly adapt cost structures to anticipated levels of business and our ability to manage inventory levels with market demand); future economic, competitive, financial and market conditions; consolidation in the global communications test, monitoring and analytics solutions markets and increased competition among vendors; capacity to adapt our future product offering to future technological changes; limited visibility with regard to the timing and nature of customer orders; delay in revenue recognition due to longer sales cycles for complex systems involving customers’ acceptance; fluctuating exchange rates; concentration of sales; timely release and market acceptance of our new products and other upcoming products; our ability to successfully expand international operations and to conduct business internationally; and the retention of key technical and management personnel. Assumptions relating to the foregoing involve judgments and risks, all of which are difficult or impossible to predict and many of which are beyond our control. Other risk factors that may affect our future performance and operations are detailed in our Annual Report, on Form 20-F, and our other filings with the U.S. Securities and Exchange Commission and the Canadian securities commissions. We believe that the expectations reflected in the forward-looking statements are reasonable based on information currently available to us, but we cannot assure you that the expectations will prove to have been correct. Accordingly, you should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this document. Unless required by law or applicable regulations, we undertake no obligation to revise or update any of them to reflect events or circumstances that occur after the date of this document.


1

Omnia operator survey: test and measurement efficiency (2020)


2

Data taken from recent Ofcom Connected Nations report 2020

 

Cision View original content:http://www.prnewswire.com/news-releases/exfo-partners-with-openreach-for-ground-breaking-full-fibre-initiative-301202238.html

SOURCE EXFO Inc.

Posted on

DermTech Announces Pricing of Public Offering of Common Stock

DermTech Announces Pricing of Public Offering of Common Stock

LA JOLLA, Calif.–(BUSINESS WIRE)–
DermTech, Inc. (Nasdaq: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the pricing of its previously announced underwritten public offering of 4,237,288 shares of its common stock at a price to the public of $29.50 per share. DermTech’s gross proceeds from the offering are expected to be approximately $125 million, before deducting underwriting discounts and commissions and offering expenses. In addition, DermTech has granted the underwriters a 30-day option to purchase up to 635,593 additional shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the offering are being sold by DermTech. DermTech currently intends to use the net proceeds from the offering to fund further commercialization of its clinical commercial tests, accelerate pipeline development and for general corporate purposes, including working capital and other general and administrative purposes.

Cowen and William Blair are acting as joint book-running managers for the offering. BTIG, Craig-Hallum and Oppenheimer & Co. are acting as lead managers for the offering, and Lake Street Capital Markets is acting as co-manager for the offering. The offering is expected to close on January 11, 2021, subject to the satisfaction of customary closing conditions.

The offering is being made only by means of a written prospectus and related prospectus supplement forming part of DermTech’s shelf registration statement on Form S-3 (File No. 333-248642) that was filed with the Securities and Exchange Commission (the “SEC”) on September 8, 2020 and declared effective by the SEC on September 17, 2020. The preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering were filed with the SEC on January 6, 2021. The final prospectus supplement and accompanying prospectus will be available at the SEC’s website located at www.sec.gov. Alternatively, copies may be obtained, when available, from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by email at [email protected] or by telephone at (833) 297-2926, or from William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by email at [email protected] or by telephone at 1-800-621-0687.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About DermTech:

DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments.

Forward-Looking Statements:

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: the completion, timing and option relating to the public offering and the anticipated amount and use of proceeds therefrom, as well as the performance, patient benefits, cost-effectiveness, commercialization and adoption of DermTech’s products and the market opportunity therefor. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; (9) the completion of the public offering; and (10) other risks and uncertainties included in the “Risk Factors” section of the preliminary prospectus filed by DermTech with the SEC on January 6, 2021, the most recent Quarterly Report on Form 10‑Q filed by DermTech with the SEC, and other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Sarah Dion

VP Marketing

[email protected]

(858) 450-4222

Investor Relations:

Caroline Corner, PhD

Westwicke, an ICR company

[email protected]

(415) 202-5678

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Oncology Medical Supplies Medical Devices Health Genetics Biotechnology

MEDIA:

Posted on

Pomerantz Law Firm Announces the Filing of a Class Action against Tricida, Inc. and Certain Officers – TCDA

PR Newswire

NEW YORK, Jan. 6, 2021 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Tricida, Inc. (“Tricida” or the “Company”) (NASDAQ: TCDA) and certain of its officers.   The class action, filed in United States District Court for the Northern District of California, and docketed under 21-cv-00076, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Tricida securities between September 4, 2019 and October 28, 2020, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are a shareholder who purchased Tricida securities during the Class Period, you have until March 8, 2021 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 


[Click here for information about joining the class action]

Tricida is a pharmaceutical company that focuses on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (“CKD”).  Tricida has completed a Phase 3, double-blind, placebo-controlled trial of veverimer in patients with CKD and metabolic acidosis.

On September 4, 2019, Tricida announced that it had submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) under the Accelerated Approval Program for approval of veverimer for the treatment of metabolic acidosis in patients with CKD.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements, and failed to disclose material adverse facts about the Company’s business, operational, and compliance policies.  Specifically, Defendants made false and/or misleading statements and failed to disclose to investors that: (i) Tricida’s NDA for veverimer was materially deficient; (ii) accordingly, it was foreseeably likely that the FDA would not accept the NDA for veverimer; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On July 15, 2020, Tricida issued a press release announcing that, on July 14, 2020, the Company received a notification from the FDA, stating that as part of the FDA’s ongoing review of the Company’s NDA for veverimer, “the FDA has identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time.”  Tricida stated that “[t]he notification does not specify the deficiencies identified by the FDA.”

On this news, Tricida’s stock price fell $10.56 per share, or 40.31%, to close at $15.64 per share on July 16, 2020.

Then, on October 29, 2020, Tricida announced an update on its End-of-Review Type A meeting with the FDA regarding the veverimer NDA, advising investors that the Company “now believes the FDA will also require evidence of veverimer’s effect on CKD progression from a near-term interim analysis of the VALOR-CKD trial for approval under the Accelerated Approval Program and that the FDA is unlikely to rely solely on serum bicarbonate data for determination of efficacy.”  Concurrently, Tricida disclosed that it “is significantly reducing its headcount from 152 to 59 people and will discuss its commitments with vendors and contract service providers to potentially provide additional financial flexibility.”

On this news, Tricida’s stock price fell $3.90 per share, or 47.16%, to close at $4.37 per share on October 29, 2020.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:

Robert S. Willoughby

Pomerantz LLP
[email protected]
888-476-6529 ext. 7980

 

Cision View original content:http://www.prnewswire.com/news-releases/pomerantz-law-firm-announces-the-filing-of-a-class-action-against-tricida-inc-and-certain-officers—tcda-301202472.html

SOURCE Pomerantz LLP

Posted on

RLH INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RLH Corporation – RLH

RLH INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RLH Corporation – RLH

NEW ORLEANS–(BUSINESS WIRE)–
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of RLH Corporation (NYSE: RLH) to Sonesta International Hotels Corporation. Under the terms of the proposed transaction, shareholders of RLH will receive only $3.50 in cash for each share of RLH that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([email protected]) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nyse-rlh/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Kahn Swick & Foti, LLC

Lewis S. Kahn

[email protected]

855-768-1857

KEYWORDS: Louisiana United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo
Posted on

SHAREHOLDER ALERT: CLAIMSFILER REMINDS BSX, SPLK INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

NEW ORLEANS, Jan. 06, 2021 (GLOBE NEWSWIRE) — ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:


Boston Scientific Corporation (BSX)


Class Period: 4/24/2019 – 11/16/2020
Lead Plaintiff Motion Deadline: February 2, 2021
SECURITIES FRAUD
To learn more, visit https://www.claimsfiler.com/cases/view-boston-scientific-corporation-securities-litigation-4


Splunk Inc. (SPLK)


Class Period: 10/21/2020 – 12/2/2020
Lead Plaintiff Motion Deadline: February 2, 2021
SECURITIES FRAUD
To learn more, visit https://www.claimsfiler.com/cases/view-splunk-inc-securities-litigation

If you purchased shares of the above companies and would like to discuss your legal rights and your right to recover for your economic loss, you may, without obligation or cost to you, contact us toll-free (844) 367-9658 or visit the case links above.

If you wish to serve as a Lead Plaintiff in the class action, you must petition the Court on or before the Lead Plaintiff Motion deadline.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com



Posted on

FLIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of FLIR Systems, Inc. – FLIR

FLIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of FLIR Systems, Inc. – FLIR

NEW ORLEANS–(BUSINESS WIRE)–
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of FLIR Systems, Inc. (NasdaqGS: FLIR​​​​​) to Teledyne Technologies Incorporated (NYSE: TDY). Under the terms of the proposed transaction, shareholders of FLIR will receive only $28.00 in cash and 0.0718 shares of Teledyne common stock for each share of FLIR that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([email protected]) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-flir/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Kahn Swick & Foti, LLC

Lewis S. Kahn

855-768-1857

[email protected]

KEYWORDS: United States North America Louisiana

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo
Posted on

Vaporesso Works with Local Vape Shops to Support Needy People in France

PR Newswire

SHENZHEN, China, Jan. 6, 2021 /PRNewswire/ — Internationally renowned vaping brand, Vaporesso, is committed to giving back to the growing number of needy people around the world as part of its Vaporesso CARE program. Through this initiative, on Christmas Eve 2020, 17 participating vape shops around France helped to distribute relief supplies of food to their local communities. With more to come in the new year, these supplies are intended to help support needy people affected by the fallout of COVID-19.

As Vaporesso grows in size and influence as an international brand, its capacity to influence positive change around the world expands. This growing ability contrasted with the COVID-19 outbreak resulted in the company ramping up corporate social responsibility initiatives throughout 2020. Through a global network of international partners, Vaporesso has been donating time, money, and energy to giving.

In France, Vaporesso CARE specifically chose the Christmas holiday as a time to give back. With COVID-19 still raging throughout the country and much of the rest of the world, many people were unable to spend time with their loved ones during the festive season. This, coupled with financial pressures meant that many people were in desperate need of support. Understanding this, Vaporesso CARE connected with local vape shops to give away free supplies, helping needy people throughout the holiday season. The food supplies have also been donated to a number of charity organizations with the intention of giving to an even wider range of people with the whole event receiving praise from a number of local media outlets such as OUEST FRANCE, LE COURRIER INDÉPENDANT and the municipality of Rives-en-Seine.

Regarding the distribution of relief supplies through French vape shops, Vaporesso Global Marketing Director, Niki Zhang, said “At Vaporesso, we take being a positive corporate citizen very seriously. Doing what we can to give back to the community is part of our global mission to make the world a better place.”

The Vaporesso CARE program is dedicated to charity and positive action projects. Initially put together to help international partners cope with the pandemic, it has since grown to represent much more than the fight against COVID-19. Vaporesso CARE is now dedicated to supporting communities around the world through working together with local vape shops and institutions and is set to continue to grow into the future.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/vaporesso-works-with-local-vape-shops-to-support-needy-people-in-france-301202448.html

SOURCE VAPORESSO

Posted on

MAGELLAN HEALTH INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Magellan Health, Inc. – MGLN

MAGELLAN HEALTH INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Magellan Health, Inc. – MGLN

NEW ORLEANS–(BUSINESS WIRE)–
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Magellan Health, Inc. (NasdaqGS: MGLN) to Centene Corporation (NYSE: CNC). Under the terms of the proposed transaction, shareholders of Magellan will receive only $95.00 in cash for each share of Magellan that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([email protected]) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-mgln/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Kahn Swick & Foti, LLC

Lewis S. Kahn

855-768-1857

[email protected]

KEYWORDS: Louisiana United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo
Posted on

SMTC CORPORATION INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SMTC Corporation – SMTC

SMTC CORPORATION INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SMTC Corporation – SMTC

NEW ORLEANS–(BUSINESS WIRE)–
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of SMTC Corporation (NasdaqGM: SMTC) to an affiliate of H.I.G. Capital. Under the terms of the proposed transaction, shareholders of SMTC will receive only $6.044 in cash for each share of SMTC that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([email protected]) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgm-smtc/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Lewis S. Kahn

[email protected]

855-768-1857

KEYWORDS: Louisiana United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo
Posted on

BOSTON PRIVATE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Boston Private Financial Holdings, Inc. – BPFH

BOSTON PRIVATE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Boston Private Financial Holdings, Inc. – BPFH

NEW ORLEANS–(BUSINESS WIRE)–
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Boston Private Financial Holdings, Inc. (NasdaqGS: BPFH) to SVB Financial Group (NasdaqGS: SIVB). Under the terms of the proposed transaction, shareholders of Boston Private will receive only 0.0228 shares of SVB common stock and $2.10 in cash for each share of Boston Private that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([email protected]) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-bpfh/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Kahn Swick & Foti, LLC

Lewis S. Kahn

855-768-1857

[email protected]

KEYWORDS: United States North America Louisiana

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo